Systemic lupus erythematosus

  title={Systemic lupus erythematosus},
  author={Jessica Manson and Anisur Rahman},
  journal={Orphanet Journal of Rare Diseases},
  pages={6 - 6}
Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease, which is autoimmune in origin and is characterized by the presence of autoantibodies directed against nuclear antigens. It is a multi-system disease, and patients can present in vastly different ways. Prevalence varies with ethnicity, but is estimated to be about 1 per 1000 overall with a female to male ratio of 10:1. The clinical heterogeneity of this disease mirrors its complex aetiopathogenesis, which highlights the… 
A study to evaluate the correlation between serological profile and histopathology of lupus nephritis.
Serological profile of SLE had significant correlation with histopathology of lupus nephritis and there can be a case for starting immunosuppressive therapy without biopsy in a known SLE patient with evidence of LN and positive serology.
Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease of unknown cause that can affect the skin, joints, kidneys, lungs, nervous system, serous membranes and other organs in the body,
Molecular Insights into Systemic Lupus Erythematosus Pathogenesis
This editorial has made an attempt to describe multistep immune alterations that pave the way for the inception and sustaining of SLE pathogenesis, and postulated molecular mechanisms involved in SLE disease onset to help in better understanding SLE etiopathogenesis.
Susceptibility genes in systemic lupus erythematosus
Two novel SLE candidate genes contributing to SLE susceptibility in several populations are identified as well as shown that a number of previously identified Sle susceptibility genes also contribute to risk in the Finnish population.
Systemic lupus erythematosus
The 10-year mortality has improved and toxic adverse effects of older medications such as cyclophosphamide and glucocorticoids have been partially offset by newer drugs such as mycophenolate mofetil and glucose-sparing regimes.
New treatment options for SLE include Belimumab, Mycophenolate mofetil, intravenous immunoglobulins, Rituximab, Atacicept etc. main purpose of addition of new treatment modalities is prevention of complications of conventional treatment and to look for better therapeutic options.
Systemic lupus erythematosus.
Clinical features of patients with systemic lupus erythematosus (SLE) attending the SLE outpatient clinic at Universitas Hospital in Bloemfontein, South Africa
The most common features of patients with systemic lupus erythematosus attending the outpatient clinic at Universitas Hospital in Bloemfontein, South Africa were determined and it can be deduced that the climate may play an important role.
Systemic lupus erythematosus in the practice of dermatology.
Clinical studies have shown that early diagnosis of systemic lupus erythematosus disease is the determining factor of a favorable prognosis of the disease.
Update on Outcome Measures for Pediatric Systemic Lupus Erythematosus
The present review provides an overview of the newer outcome measures specifically developed for use in patients with pSLE, and discusses the need for a careful longterm followup of currently treated patients.


Genetics of human systemic lupus erythematosus: the emerging picture.
Pathogenesis of systemic lupus erythematosus
  • C. Mok, C. Lau
  • Medicine, Biology
    Journal of clinical pathology
  • 2003
The exact patho-aetiology of systemic lupus erythematosus (SLE) remains elusive. An extremely complicated and multifactorial interaction among various genetic and environmental factors is probably
Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome.
Complement and systemic lupus erythematosus
The role of the complement system in SLE is reviewed and hypotheses are advanced to explain the complex relationships between complement and lupus.
Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus.
It is established that the presence of annular skin lesions can serve as a cutaneous marker for a distinct subset of patients with lupus erythematosus who share similar clinical, serologic, and genetic features.
High prevalence of platelet autoantibodies in patients with systemic lupus erythematosus
The prevalence of PAA in SLE patients is high and should be regarded as one of the multiple serological abnormalities which may develop in these patients, although some patients with PAA had a normal platelet count.
SLE--a disease of clearance deficiency?
The cells, receptors and molecules involved in the clearance process are addressed and it is shown how deficiencies in this process may contribute to the aetiopathogenesis of SLE.
A distinctive autoantibody profile in black female patients with lupus nephritis.
While the mechanism responsible for the relationship of this distinctive serologic profile to the development of nephritis in black female lupus patients remains to be determined, its presence may be used as a marker for severe and progressive renal disease.
Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients
Doctors should be cautious in prescribing high doses of corticosteroids or immunosuppressants to patients with SLE solely because they have high titers of ACLA, and it is proposed that such criteria could be applied to the definition of the antiphospholipid syndrome.
Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus.
The data suggest that IgG antinucleosome is a new marker that may help in the differential diagnosis of CTD; antin nucleosome of the IgG3 isotype might constitute a selective biologic marker of active SLE, in particular, of lupus nephritis.